Skip to main content
XWEL
NASDAQ Trade & Services

Chairman Bruce Bernstein Discloses 6.9% Stake and Commits to Vote for $13M Asset Sale

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Diagnostics & Research Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$1.04
Mkt Cap
$8.782M
52W Low
$0.255
52W High
$2.2
52W Position info
308% above low
Off High info
53% below high
Rel. Volume info
0.3× avg
Market data snapshot near publication time

XWEL has more than doubled off its 52-week low of $0.255 on light trading volume (0.3× avg).

Summary

XWELL Chairman Bruce Bernstein disclosed a 6.9% stake and agreed to vote for the $13M sale of XpresSpa and XpresTest, locking in insider support for the pending transaction.


Key Events · Ownership and Investor Activity · XWEL

  • Chairman Discloses 6.9% Stake

    Bruce Bernstein beneficially owns 602,556 shares (6.9% of outstanding), including 294,565 shares issuable upon exercise of vested options.

  • Voting Support for Asset Sale

    Bernstein entered a Support Agreement on July 6, 2026, committing to vote all his shares in favor of the $13 million sale of XpresSpa and XpresTest to Express Wellness Group.

  • Historical Equity Grants

    Bernstein received 220,528 options and 200,926 restricted shares in June 2025, 100,000 restricted shares in February 2026, and earlier option grants, all as compensation for his role as Chairman.

  • Prior Open-Market Purchase

    Between November 30 and December 1, 2022, Bernstein bought 7,065 shares for approximately $21,097 of personal funds.


Analysis · XWEL · Trade & Services

Bruce Bernstein, Chairman of XWELL, filed his initial Schedule 13D revealing a 6.9% beneficial ownership stake (602,556 shares including options) and a binding Support Agreement to vote all his shares in favor of the pending $13 million sale of XpresSpa and XpresTest. The filing also details a series of equity grants received since 2023, including 220,528 options and 200,926 restricted shares in mid-2025, and a small open-market purchase in late 2022. The voting commitment is material because it locks in support from a key insider for the transformative asset sale, which requires stockholder approval and is central to the company's pivot strategy. The disclosure provides transparency on the Chairman's alignment with the deal and his compensation history, but the stake size is modest relative to the company's micro-cap valuation.

At the time of this filing, XWEL was trading at $1.04 on NASDAQ in the Trade & Services sector, with a market capitalization of approximately $8.8M. The 52-week trading range was $0.26 to $2.20. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

XWEL - Latest Insights

XWEL
Jul 24, 2026, 5:39 PM EDT
Filing Type: PREM14A
Importance Score:
8
XWEL
Jul 09, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
9
XWEL
May 20, 2026, 4:11 PM EDT
Source: Wiseek News
Importance Score:
9
XWEL
May 20, 2026, 4:05 PM EDT
Filing Type: 10-Q
Importance Score:
9
XWEL
Apr 16, 2026, 4:05 PM EDT
Filing Type: 424B3
Importance Score:
9